Pfizer Aromasin Cleared For Early Breast Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer's oncologic Aromasin (exemestane) received approval Oct. 5 for the adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy
You may also be interested in...
Novartis Submits Femara For Early Adjuvant Treatment Of Breast Cancer
Femara would be first breast cancer drug with adjuvant and extended adjuvant approvals, Novartis says. Supplemental NDA is based on a reduction of the risk of recurrence in the BIG 1-98 trial; the 8,000-patient study is continuing to determine if monotherapy or sequential therapy with tamoxifen is more effective.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.